目的 觀察達那唑栓治療子宮內膜異位癥的療效及不良反應。方法 選擇曾行開腹或腹腔鏡手術確診的子宮內膜異位癥再次復發(fā)患者87例，隨機單盲分為兩組，其中達那唑栓組46例，第一個月每晚2粒，之后每晚1粒，陰道或肛門用藥，療程6個月。達那唑膠囊對照組41例，口服給藥，2次/d，療程6個月，定期隨訪。比較應用達那唑栓及達那唑膠囊治療子宮內膜異位癥的癥狀、體征變化及不良反應情況。結果 達那唑栓組痛經、非經期下腹痛、性交痛、后陷凹結節(jié)、肛門墜痛的改善率與達那唑膠囊組比較，差異均無統(tǒng)計學意義（P＞0.05）。達那唑栓組體質量改變、轉氨酶升高、陰道異常出血、閉經及痤瘡不良反應發(fā)生率顯著低于達那唑膠囊組，差異有統(tǒng)計學意義（P＜0.05）。結論 達那唑栓治療復發(fā)性子宮內膜異位癥與達那唑膠囊療效相當，但不良反應較達那唑膠囊明顯減少，安全性高。

Objective To observe the efficacy and adverse reactions of Danazol Suppository (DS) in the treatment of recurrent endometriosis. Methods Eighty-seven patients with recurrent endometriosis diagnosed by open and laparoscopic operation were randomly single-blind divided into two groups. DS group with 46 cases was administrated with two pills in the first month every evening and then one pill every evening via vaginal or anal administration, and the course was six months. The control group with 41 cases was po administrated with Danazol Capsule (DC) twice daily, for six months and regular follow-up. The symptoms, physical signs, and adverse reactions of DS and DC in the treatment of recurrent endometriosis were observed and compared. Results There were no significant differences in the improvement rates of dysmenorrhea, lower abdominal pain in non menstrual, the pain during pareunia and after excavation nodules, and rectal pain between DS and DC groups (P >0.05). But in DS group, the incidence of body weight change, elevated transaminases, abnormal vaginal bleeding, amenorrhea, and acne adverse reaction was significantly lower than that in DC group (P<0.05). Conclusion The effect of DS in the treatment of recurrent endometriosis is similar to that of DC, but adverse reactions are significantly decreased compared with DC,in high security.